# Cardea Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardea-bio

- Industry: Semiconductors
- Headquarters: San Diego, US
- Website: www.cardeabio.com
- Total disclosed funding: $14M
- Latest round: Series A (Jan 12, 2021)
- Investors on record: 7

## About

Based in the US, Cardea Bio Inc. develops innovative biosensing technologies utilizing bioelectronic systems to improve healthcare diagnostics and environmental monitoring applications.Cardea Bio Inc. specializes in bioelectronic systems that leverage biology to enable advanced sensing capabilities. Founded in 2014 and headquartered in San Diego, California, the company was co-founded by Kiana Aran and Ross Bundy. The latest round of funding was a Grant of USD 1.1 mn led by the Bill & Melinda Gates Foundation Trust on April 30, 2023, bringing the total amount raised to USD 6.5 mn. The company has participated in a total of 7 deals, with no notable pivots or changes in its business strategy reported.Cardea Bio Inc. specializes in advanced biosensing technology, particularly through its innovative bioelectronic systems designed for a variety of applications. The flagship product incorporates unique biosensors that facilitate versatile molecule sensing for healthcare diagnostics and environmental monitoring. These systems are designed to detect various biological and chemical substances, ensuring high sensitivity and specificity. The company markets its products globally, focusing on regions such as North America, Europe, and Asia-Pacific, to meet the increasing demand for accurate and reliable sensing technologies.Cardea Bio Inc. generates revenue through the direct sales of its biosensing products to healthcare institutions, laboratories, and industries needing advanced analytical solutions. The business model is primarily B2B, focusing on building partnerships and direct sales channels that enhance customer access to their technologies. Revenue comes from both direct sales and ongoing collaborations, reflecting the company’s commitment to providing tailored solutions and support for specific application needs.Following the acquisition by Paragraf Limited in April 2023, which will see its renaming to Paragraf USA, Cardea Bio Inc. aims to accelerate its entry into the US market. The recent funding will be directed towards mass production of new biosensing products designed for expanded applications in healthcare and environmental monitoring. The company plans to launch additional products within the next year and expand its market presence across North America, Europe, and Asia-Pacific by 2024.

## Funding rounds

- Series A, Jan 12, 2021, $6.5M — 3E Bioventures Capital
- Series A, Sep 17, 2020, $7.5M — Agilent Technologies, Serra Ventures, Table Mountain Capital, Foothill Ventures, Photon Fund, Taihill Venture

## Investors

- Agilent Technologies — Series A
- Serra Ventures (https://capitalatlas.ai/funds/serra-ventures) — Series A
- Table Mountain Capital — Series A
- Foothill Ventures (https://capitalatlas.ai/funds/foothill-ventures) — Series A
- Photon Fund (https://capitalatlas.ai/funds/photon-fund) — Series A
- Taihill Venture (https://capitalatlas.ai/funds/taihill-venture) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A